Schlatter J, Kabiche S, Sellier N, Fontan J-E
Service pharmacie clinique, hôpital universitaire Necker-Enfants-Malades, 149, rue de Sèvres, 75015 Paris, France.
Service pharmacie clinique, hôpital Jean-Verdier, hôpitaux universitaires de Paris-Seine-Saint-Denis, Bondy, France.
Ann Pharm Fr. 2018 Jul;76(4):286-290. doi: 10.1016/j.pharma.2018.03.002. Epub 2018 Apr 11.
The efficacy and safety of an oral pentobarbital suspension for sedation during pediatric MR imaging were assessed.
Data were recorded from October 2016 to January 2017. The exact dose of oral pentobarbital suspension was given for each child with an oral syringe. Parameters recorded included the patient's age and weight, the time required to sedate, the duration of sedation, the time required to discharge, and quality of MR imaging. The adverse effects were recorded.
Oral pentobarbital suspension was administered to 81 children aged from 8 months to 8 years at a dose of 5mg/kg of body weight. The mean time required to sedate was 30±21min, a mean time of sedation of 47±23min, and a mean time to discharge of 77±32min. Sedation occurred a satisfied quality of MR imaging in 67% of patients. The failure of examination was essentially due to bad taste of the drug suspension. The overall success rate of sedation in patients less than 12 months was 100%. For ages 1 to 3 years, the success rate decreased to 76% and for ages 4 to 8 years, it decreased to 42%.
Oral pentobarbital suspension used in MR imaging demonstrated its high rate of successful sedation in infants less than 12 months with no adverse effects during the study period.
评估口服戊巴比妥混悬液在小儿磁共振成像(MR成像)镇静过程中的有效性和安全性。
记录2016年10月至2017年1月的数据。用口服注射器为每个儿童给予确切剂量的口服戊巴比妥混悬液。记录的参数包括患者的年龄和体重、镇静所需时间、镇静持续时间、出院所需时间以及MR成像质量。记录不良反应。
81名年龄在8个月至8岁的儿童接受了口服戊巴比妥混悬液治疗,剂量为5mg/kg体重。镇静平均所需时间为30±21分钟,平均镇静时间为47±23分钟,平均出院时间为77±32分钟。67%的患者镇静时MR成像质量良好。检查失败主要是由于药物混悬液味道不佳。12个月以下患者的总体镇静成功率为100%。1至3岁时,成功率降至76%,4至8岁时,降至42%。
用于MR成像的口服戊巴比妥混悬液在12个月以下婴儿中显示出高镇静成功率,且在研究期间无不良反应。